000			04034nam a22004215i 4500
999			_c11468 _d11468
001			11468
003			DE-He213
005			20210713040332.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			180803s2018 gw | s |||| 0|eng d
020			_a9783319787626
024	7		_a10.1007/978-3-319-78762-6 _2doi
040			_bspa _dES-MaUEC
050		4	_aRC280 _b.M65 2018 EB
245	0	0	_aMolecular Determinants of Head and Neck Cancer _cedited by Barbara Burtness, Erica A. Golemis.
250			_a2nd ed. 2018.
264		1	_aCham _bSpringer International Publishing : _bImprint: Humana Press _c2018.
300			_a1 recurso en línea ( VI, 629 páginas, 68 ilustraciones, 62 ilustraciones a color)
336			_2rdacontent _aTexto (visual) _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_atext file _bPDF _2rda
490	0		_aCurrent Cancer Research _x2199-2584
490	0		_aMedicine (Springer-11650)
520			_aSquamous cell cancers of the head and neck (SCCHN), also known as head and neck cancers (HNC) encompass malignancies of the oral cavity, larynx, nasopharynx and pharynx, and are diagnosed in over 500,000 patients worldwide each year, accounting for 5% of all malignancies. It is estimated that approximately 50,000 patients develop head and neck cancer annually in the United States, of whom approximately 50% succumb to this cancer. For most cases of SCCHN, treatment is multimodal, often combining surgery or irradiation with chemotherapy; even successfully treated patients frequently experience durable and severe side effects. Improving cure rates and reducing chronic morbidity are urgent clinical needs for head and neck cancer. However, in contrast to cancer types such as breast or prostate that have been much studied and have well-defined biology, until recently, relatively few researchers investigated the molecular basis of HNC, making it difficult to design targeted treatments with better efficacy and less debilitating side effects. This volume will provide an overview of the factors contributing to disease pathogenesis, including the recognition of discrete molecular subtypes with distinct etiology, prognosis, and treatment response. This volume will familiarize the reader with the critical signaling pathways and oncogenic drivers for HNC. It will outline the differences between HPV-positive and HPV-negative disease, and how these differences affect treatment choice and outcome. The book will emphasize developments in the past five years, including the growing understanding of the genomic and epigenomic features of the disease based on analysis of next generation sequencing (NGS) data, and timely topics such as the analysis of HNC stem cell populations, non-coding mRNAs, and inflammatory response. It will address exciting new therapeutic approaches such as the use of immunotherapies to treat HNC patients. Overall, the book will provide the reader with current understanding of the biology and treatment of the disease, and describe timely questions that will guide future research aimed at controlling and curing this disease.
650		7	_2embne _9210886 _aCabeza _xCáncer
650		7	_2embne _9210887 _aCuello _xCáncer
700	1		_aBurtness, Barbara _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt _0http://id.loc.gov/authorities/names/n2014187697 _988220
700	1		_aGolemis, Erica A _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt _988221
710	2		_aSpringerLink (Online service) _0http://id.loc.gov/authorities/names/no2005046756 _9106996
776	0	8	_iPrinted edition: _z9783319787619
776	0	8	_iPrinted edition: _z9783319787633
776	0	8	_iPrinted edition: _z9783030087791
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-319-78762-6 _zAcceso a este recurso digital (usuarios Universidad Europea de Valencia)
942			_2lcc _cLE
998			_db _feng _ggw _h0